These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 33164611)

  • 1. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study.
    Takeuchi T; Rischmueller M; Blanco R; Xavier RM; Ueki Y; Atsumi T; Chen S; Friedman A; Pangan AL; Strand V; van Vollenhoven RF
    Mod Rheumatol; 2021 May; 31(3):534-542. PubMed ID: 33164611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.
    van Vollenhoven R; Strand V; Takeuchi T; Chávez N; Walter PM; Singhal A; Swierkot J; Khan N; Bu X; Li Y; Penn SK; Camp HS; Aelion J
    Arthritis Res Ther; 2024 Jul; 26(1):143. PubMed ID: 39075620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
    Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.
    van Vollenhoven R; Takeuchi T; Pangan AL; Friedman A; Mohamed MF; Chen S; Rischmueller M; Blanco R; Xavier RM; Strand V
    Arthritis Rheumatol; 2020 Oct; 72(10):1607-1620. PubMed ID: 32638504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.
    Fleischmann R; Swierkot J; Penn SK; Durez P; Bessette L; Bu X; Khan N; Li Y; Peterfy CG; Tanaka Y; Mysler E
    RMD Open; 2024 May; 10(2):. PubMed ID: 38806190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
    Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
    Fleischmann RM; Genovese MC; Enejosa JV; Mysler E; Bessette L; Peterfy C; Durez P; Ostor A; Li Y; Song IH
    Ann Rheum Dis; 2019 Nov; 78(11):1454-1462. PubMed ID: 31362993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
    Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Zhou Y; Othman AA; Pangan AL; Kitamura S; Meerwein S; Tanaka Y
    Rheumatology (Oxford); 2020 Nov; 59(11):3303-3313. PubMed ID: 32277824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
    Peterfy CG; Strand V; Friedman A; Hall S; Mysler E; Durez P; Baraliakos X; Enejosa JV; Shaw T; Li Y; Chen S; Song IH
    Rheumatology (Oxford); 2022 Aug; 61(8):3246-3256. PubMed ID: 34897366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
    Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Yokoyama M; Pangan AL; Konishi Y; Meerwein S; Tanaka Y
    Arthritis Res Ther; 2021 Jan; 23(1):9. PubMed ID: 33407801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
    Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Iwasaki M; Katayama K; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Shiomi T; Yamada E; van der Heijde D
    Ann Rheum Dis; 2019 Oct; 78(10):1305-1319. PubMed ID: 31350269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
    Lee YH; Song GG
    Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
    Strand V; Tundia N; Wells A; Buch MH; Radominski SC; Camp HS; Friedman A; Suboticki JL; Dunlap K; Goldschmidt D; Bergman M
    Rheumatology (Oxford); 2021 Jul; 60(7):3209-3221. PubMed ID: 33313898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
    Yamaoka K; Tanaka Y; Kameda H; Khan N; Sasaki N; Harigai M; Song Y; Zhang Y; Takeuchi T
    Drug Saf; 2021 Jun; 44(6):711-722. PubMed ID: 34041702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
    Fleischmann R; Curtis JR; Charles-Schoeman C; Mysler E; Yamaoka K; Richez C; Palac H; Dilley D; Liu J; Strengholt S; Burmester G
    Ann Rheum Dis; 2023 Sep; 82(9):1130-1141. PubMed ID: 37308218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.